- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01109706
Relevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome. (PC-SCA-9)
PCSK9 (Proprotein convertase subtilisin kexin type 9) plays a key role in LDL-cholesterol (LDLC) metabolism by inhibiting LDL receptor (LDLR) at post-transcriptional level. PCSK9 loss of function mutations are associated to decreased LDLC levels and a cardiovascular protection. In this context, the development of pharmacological inhibitors of PCSK9, in association with statins treatment, represents a major therapeutic issue for LDLC modulation. It was previously shown that PCSK9 plasmatic concentration correlated with plasmatic LDLC, TG and glucose concentrations. However, no data are available on predictive value of PCSK9 plasmatic level concerning coronary disease severity.
The main objective of this study is to determine whether plasmatic PCSK9 concentration is linked to coronary damage severity in patients with acute coronary syndrome.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Nantes, Frankrig, 44093
- Nantes University Hospital
-
Nantes, Frankrig, 44000
- Nantes University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion criteria:
- more than 18 years old
- Acute coronary syndrome (ST+ or ST-)
- 2 groups of patients: with statin, and without statin treatment
Exclusion criteria:
- Patient who had cancer during the last 5 years or with cancer in progress
- Patient with severe infection in progress
- Hepatic failure (TP<50%)
- Severe kidney failure
- Patient unable to give his consent to the study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: Andet
- Tidsperspektiver: Fremadrettet
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
patient treated by statines
|
200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin). After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment). Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up. |
patient without normolipidemic treatment
|
200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin). After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment). Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Syntax score (for evaluate coronary damages) and plasmatic concentration of PCSK9
Tidsramme: Day 1, Day 2, Day 3, Day 4
|
Assessing the correlation between plasma concentration of PCSK9 and coronary damage severity in patients with acute coronary syndrome.
Coronary lesions will be measured using the SYNTAX score (J0: admission day), and PCSK9 concentration will be evaluated using blood analysis (J0 (admission), J1, J2, J3 & J4).
|
Day 1, Day 2, Day 3, Day 4
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Correlation between PCSK9 and morbidity/mortality
Tidsramme: Day 1, Day 2, Day 3, Day 4
|
Assessing the correlation between plasma PCSK9 (J1, J2, J3, J4) concentration and one-year morbidity/mortality of patients with acute coronary syndrome
|
Day 1, Day 2, Day 3, Day 4
|
association between PCSK9 and metabolic/inflammatory factors
Tidsramme: Day 1, Day 2, Day 3, Day 4
|
Identification of metabolic and inflammatory factors (glycemia, insulinemia, HbA1C, CRPus…) associated to plasma PCSK9 concentration
|
Day 1, Day 2, Day 3, Day 4
|
kinetic of PCSK9 for statin-treated patients
Tidsramme: Day 1, Day 2, Day 3, Day 4
|
Measurement of PCSK9 kinetic variation during ACS acute phase in patients treated with artovastatin 80 mg/day (J1, J2, J3, and J4)
|
Day 1, Day 2, Day 3, Day 4
|
kinetic of PCSK9 after intensive care
Tidsramme: Day 1, Day 2, Day 3, Day 4
|
Determination of PCSK9 kinetic variation at 1 and 6 months after intensive care, during their normal follow-up
|
Day 1, Day 2, Day 3, Day 4
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Bertrand Cariou, MD, Nantes University Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- BRD/10/03-ZE
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Akut koronarsyndrom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aorta origin of the coronary artery (AAOCA)Italien
-
Riphah International UniversityAfsluttet
-
Shaare Zedek Medical CenterUkendtPræmenstruelt syndrom - PMS
-
Riphah International UniversityAfsluttet
-
Esra ÖZERKTO Karatay UniversityRekrutteringEffekten af aromaterapiapplikation med bergamot og grapefrugt æteriske olier på PMS (Aromatherapy)Præmenstruelt syndrom - PMSKalkun
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, ikke rekrutterendePOMES syndrom | Tilbagefaldende og refraktær POMES-syndromKina
-
Riphah International UniversityRekrutteringNedre kors syndromPakistan
-
Foundation University IslamabadRekruttering
-
University of CalgaryUkendtNefrotisk syndrom hos børn | Nefrotisk syndrom, minimal ændring | Nefrotisk syndrom, idiopatiskCanada
Kliniske forsøg med biological parameters dosage
-
Centers for Disease Control and Prevention, ChinaBeijing Tiantan Biological Products Co., Ltd.AfsluttetMæslinger | Røde hunde | Fåresyge | Bivirkning efter vaccinationKina
-
Hualan Biological Engineering, Inc.Afsluttet
-
Jiangsu Province Centers for Disease Control and...Beijing Minhai Biotechnology Co., LtdAfsluttet
-
Jiangsu Province Centers for Disease Control and...AfsluttetUønsket virkning og immunogenicitet af vaccineKina
-
Tianjin Medical University Cancer Institute and...Rekruttering
-
Shanghai Institute Of Biological ProductsAfsluttet